(PharmaNewsWire.Com, July 10, 2021 ) The global pyrogen testing market size is projected to reach USD 1,689 million by 2025 from USD 927 million in 2020, at a CAGR of 12.7%. Market growth is driven by the growing focus on personalized medicine, increasing R&D in the pharmaceutical and biotechnology industries, rising prevalence of chronic diseases, the growing awareness of food safety, and the rising incidence of infectious diseases and increasing frequency of pandemics.
Charles River Laboratories, Inc.(US) Lonza(Switzerland) Merck KGaA(Germany) Thermo Fisher Scientific, Inc. (US) “In 2019, assays, kits, & reagents segment accounted for the largest share of the pyrogen testing market, by product & service”
Based on product & service, the pyrogen testing market is segmented into assays, kits, and reagents; instruments; and services. The assays, kits, & reagents segment accounted for the largest share in the pyrogen testing market in 2019. The rising preference for kit-based testing and the frequent requirement of assays, kits, and reagents in large numbers as compared to instruments are the major factors driving the growth of this segment.
In 2019, LAL tests segment accounted for the largest share in the market, by test type
The pyrogen testing market is segmented into LAL tests, in vitro tests, and rabbit tests based on test type. In 2019, the LAL tests segment accounted for the largest share. This can be attributed to the rapid growth in the pharmaceutical and biotechnology industries, increasing demand for medical devices, increasing health standards, rising need for innovative laboratory testing procedures, and the growing drug pipelines.
North America is the largest regional market for pyrogen testing
The global pyrogen testing market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. In 2019, North America accounted for the largest share of the global pyrogen testing market. The North American pyrogen testing market's growth can be attributed to the high spending on pharmaceutical and biopharmaceutical research, increasing pharmaceutical drug pipelines, a growing number of drug approvals, and rising consumer awareness about product safety.
Recent Developments In October 2020, Lonza (Switzerland) launched the PyroCell Monocyte Activation Test System for reliable and sustainable in vitro pyrogen testing. In December 2018, Eurofins Scientific acquired EAG Laboratories. This acquisition will further strengthen Eurofins’ global offering in the biopharmaceutical testing markets. In May 2018, bioMérieux SA (France) launched ENDOZYMEII GO, an innovative test for detecting endotoxins in pharmaceutical grade water, injectable drugs, and other pharmaceutical products.
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
